NASDAQ · Biotechnology

LB Pharmaceuticals Inc (LBRX) Stock

$34.61 +1.32% NASDAQ: LBRX Healthcare

Valuation

MetricValue
Price$34.61
Market Cap$992.50M
P/E Ratio-12.45
P/B Ratio3.35
P/S Ratio0.00
EPS (TTM)$-1.00
52-Week High$50.16
52-Week Low$14.32
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-25.91%
ROA-23.69%
ROCE-28.14%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio44.00

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-3.0M$-11.0M$-65.0M$-30.0M
Net Profit$-14.0M$-6.0M$-63.0M$-25.0M
EPS$-4.05$-1.77$-17.83$-1.00
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets$21.0M$46.0M$34.0M$313.0M
Total Liabilities$50.0M$80.0M$128.0M$12.0M
Cash$21.0M$15.0M$23.0M$250.0M
Borrowings$24.0M$0$4.0M$4.0M

Latest News

LB Pharmaceuticals Expects Phase-3 Schizophrenia Study's Topline Data in H1 2027 MT Newswires · Jul 22, 2026 LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia GlobeNewswire · Jul 22, 2026 Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls The Fly · Jul 21, 2026 BMO Capital Initiates LB Pharmaceuticals at Outperform With $46 Price Target MT Newswires · Jul 21, 2026 LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 10, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-3.0M$-12.0M$-53.0M$-35.0M
Investing Cash Flow$0$-28.0M$22.0M$-40.0M
Financing Cash Flow$-3.0M$-2.0M$-2.0M$0
Net Cash Flow$20.0M$-6.0M$8.0M$227.0M
Free Cash Flow$-3.0M$-12.0M$-54.0M$-35.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.07
EV / EBITDA-8.93
FCF Yield-7.81%
Quick Ratio15.08
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.42 +1.11% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $522.61 -1.35% 28.68 $3.88T 0.76%
GOOGLAlphabet Inc. $348.29 -0.63% 16.94 $4.22T 0.26%
AMZNAmazon.com, Inc. $254.06 -2.25% 19.82 $2.73T 0.00%
METAMeta Platforms, Inc. $720.89 -0.06% 27.93 $1.84T 0.28%

About LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is led by CEO Heather D. Turner, publicly traded since 2025.

LB Pharmaceuticals Inc (LBRX) stock trades at $34.61 with a market capitalization of $992.50M. The stock is valued at a price-to-earnings (P/E) ratio of -12.45, price-to-book of 3.35, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $14.32 and $50.16, and currently trades 31.0% below its 52-week high.

On profitability, LB Pharmaceuticals Inc generates a return on equity (ROE) of -25.91%, return on capital employed of -28.14%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides